Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(146 productos)
- Bcr-Abl(102 productos)
- EGFR(572 productos)
- FAK(72 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(245 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(79 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(268 productos)
Mostrar 6 subcategorías más
Se han encontrado 1431 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
c-ABL-IN-2
CAS:<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Fórmula:C21H20N4OForma y color:SolidPeso molecular:344.41JNJ-47117096 hydrochloride
CAS:<p>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.</p>Fórmula:C21H23ClN4O2Forma y color:SolidPeso molecular:398.89Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Forma y color:SolidPeso molecular:591.12MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Fórmula:C21H23N3OSPureza:98%Forma y color:SolidPeso molecular:365.49HIV-IN-6
CAS:<p>HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.</p>Fórmula:C20H16N4O3SPureza:97.12%Forma y color:SolidPeso molecular:392.43Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Forma y color:SolidPeso molecular:359.42JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSForma y color:SolidPeso molecular:358.89Squarunkin A hydrochloride
CAS:<p>Squarunkin A HCl inhibits UNC119-cargo binding, specifically blocks Src kinase activation, IC50=10 nm.</p>Fórmula:C25H33ClF3N5O4Forma y color:SoildPeso molecular:560.02TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Fórmula:C29H31F3N8OPureza:98%Forma y color:SolidPeso molecular:564.6EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SForma y color:SolidPeso molecular:385.44T338C Src-IN-2
CAS:<p>T338C Src-IN-2: Potent c-Src T338C kinase inhibitor; IC50: 317 nM, T338C/V323A: 57 nM, T338C/V323S: 19 nM.</p>Fórmula:C17H18FN5OPureza:98%Forma y color:SolidPeso molecular:327.36PD180970
CAS:<p>PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.</p>Fórmula:C21H15Cl2FN4OPureza:98.67%Forma y color:SolidPeso molecular:429.27DB07107
CAS:<p>DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).</p>Fórmula:C23H22N4OPureza:98%Forma y color:SolidPeso molecular:370.45KL-1156
CAS:<p>KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.</p>Fórmula:C17H17NO4Pureza:98%Forma y color:SolidPeso molecular:299.32FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Fórmula:C23H26F3N7O2Forma y color:SolidPeso molecular:489.49Rogaratinib
CAS:<p>Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR).</p>Fórmula:C23H26N6O3SPureza:99.54%Forma y color:SolidPeso molecular:466.56EGFR-IN-88
CAS:<p>EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis</p>Fórmula:C22H18Cl2N4O2SPureza:98%Forma y color:SolidPeso molecular:473.37BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Forma y color:SolidPeso molecular:454.49TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41FGFR4-IN-5
CAS:<p>FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.</p>Fórmula:C23H23Cl2N5O5Forma y color:SolidPeso molecular:520.37EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6DPPY
CAS:<p>DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.</p>Fórmula:C25H26ClN7O3Forma y color:SolidPeso molecular:507.97TX-1918
CAS:<p>TX-1918, a tyrphostin, blocks eEF-2K to hinder HepG2, HCT116 cell growth.</p>Fórmula:C14H12O3Forma y color:SolidPeso molecular:228.24PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Fórmula:C27H39N9OForma y color:SolidPeso molecular:505.66FGFR2-IN-2
CAS:<p>FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.</p>Fórmula:C23H22N4OPureza:98.09%Forma y color:SolidPeso molecular:370.45JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86KRC-108
CAS:<p>KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.</p>Fórmula:C20H20N6OForma y color:SolidPeso molecular:360.41BTK inhibitor 10
CAS:<p>BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.</p>Fórmula:C25H23N5O3Pureza:98%Forma y color:SolidPeso molecular:441.48J-1048
CAS:<p>J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/</p>Fórmula:C23H17FN6S2Forma y color:SolidPeso molecular:460.55Flonoltinib
CAS:<p>Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.</p>Fórmula:C25H34FN7OPureza:99.52%Forma y color:SolidPeso molecular:467.58SJF620
CAS:<p>SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).</p>Fórmula:C41H44N8O7Pureza:98%Forma y color:SolidPeso molecular:760.84YF-452
CAS:<p>YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.</p>Fórmula:C24H26BrN3OPureza:98%Forma y color:SolidPeso molecular:452.39CJ-2360
CAS:<p>CJ-2360 is a potent ALK inhibitor, effective on wild-type and various mutants, with IC50 values ranging from 2.2 to 8.9 nM, also targeting 468 kinases.</p>Fórmula:C27H30FN5O2Forma y color:SolidPeso molecular:475.56VEGFR-2-IN-6
CAS:<p>VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis [1].</p>Fórmula:C20H21N7O2SPureza:99.01%Forma y color:SolidPeso molecular:423.49Multi-kinase-IN-3
CAS:<p>Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).</p>Fórmula:C33H33N5O3Forma y color:SolidPeso molecular:547.65VEGFR-2-IN-30
<p>VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.</p>Fórmula:C28H23ClN6O4S2Forma y color:SolidPeso molecular:607.1Naphazoline
CAS:<p>Naphazoline (Naphcon-a) is a sympathomimetic compound with marked alpha adrenergic activity.</p>Fórmula:C14H14N2Pureza:99.79%Forma y color:White Crystalline Powder SolidPeso molecular:210.27NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23VEGFR-2-IN-21
CAS:<p>VEGFR-2-IN-21 is a potent inhibitor of VEGFR-2 (IC50: 0.10 μM) and exhibits anticancer effects.</p>Fórmula:C28H24ClN7O3SForma y color:SolidPeso molecular:574.05ALK5-IN-30
CAS:<p>ALK5-IN-30 (EX-07) is a potent inhibitor of ALK with inhibitory effects on ALK5 (IC50< 10 nM) and TGFβ-R1 (IC50< 10 nM).</p>Fórmula:C24H25FN8Forma y color:SolidPeso molecular:444.51BTK-IN-24
CAS:<p>BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.</p>Fórmula:C26H19F4N5O2Pureza:99.61%Forma y color:SolidPeso molecular:509.46VEGFR-2-IN-22
CAS:<p>VEGFR-2-IN-22 blocks VEGFR-2/beta-tubulin, IC50=19.82 nM, induces apoptosis.</p>Fórmula:C26H24ClFN4O6Forma y color:SolidPeso molecular:542.94FLT3-IN-15
CAS:<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.91EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51VI 16832
CAS:<p>VI 16832 is a broad-spectrum Type I kinase inhibitor used to quantify relative kinase abundance and study signaling across SILAC-encoded cancer cell lines.</p>Fórmula:C22H25N5O2Pureza:98%Forma y color:SolidPeso molecular:391.47SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Fórmula:C24H26N8O3Forma y color:SolidPeso molecular:474.52FGFR-IN-7
CAS:<p>FGFR-IN-7: Oral FGFR modulator, crosses blood-brain barrier, neuroprotective, phospholipidosis-resistant, useful for neurodegeneration study.</p>Fórmula:C16H21ClF2N4O2Forma y color:SolidPeso molecular:374.81EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4Rac-ZINC4085554
CAS:<p>Compound 1T-0219 (SC) is a blocker of AKT1-FAK interaction reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620</p>Fórmula:C20H19N3O7Pureza:90%Forma y color:SolidPeso molecular:413.38Lck Inhibitor III
CAS:<p>Lck Inhibitor III, a potent inhibitor of Lck, exhibits an IC50 value of 867 nM.</p>Fórmula:C25H30N6O4Forma y color:SolidPeso molecular:478.54K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Fórmula:C15H13F2N7O2S2Pureza:99.12%Forma y color:SolidPeso molecular:425.44EGFR/BRAFV600E-IN-1
CAS:<p>EGFR/BRAFV600E-IN-1 inhibits EGFR (0.08 μM) & BRAFV600E (0.15 μM), affects A-549, MCF-7, Panc-1 & HT-29 (IC50: 0.79-1.3 μM).</p>Fórmula:C24H24ClN3O3Forma y color:SolidPeso molecular:437.92PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OForma y color:SolidPeso molecular:342.44GW694590A
CAS:<p>GW694590A (UNC10112731) functions as a MYC protein stabilizer that enhances the levels of endogenous MYC protein. It also acts on receptor tyrosine kinases, inhibiting DDR2, KIT, and PDGFRα by 81%, 68%, and 67% at a concentration of 1 μM, respectively. As a protein kinase inhibitor, GW694590A affects both ATP-dependent and ATP-independent luciferases, potentially influencing the Fluc reporter gene [1].</p>Fórmula:C22H19N5O4Forma y color:SolidPeso molecular:417.42TGFBR1-IN-1
CAS:<p>TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).</p>Fórmula:C23H17N5O2SPureza:98%Forma y color:SolidPeso molecular:427.48NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39ACP-5862
CAS:<p>ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.</p>Fórmula:C26H23N7O3Forma y color:SolidPeso molecular:481.51Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Fórmula:C28H23ClF3N7O2Forma y color:SolidPeso molecular:581.98BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51FM19G11
CAS:<p>FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).</p>Fórmula:C23H17N3O8Pureza:99.70%Forma y color:SolidPeso molecular:463.4EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44Antiproliferative agent-30
CAS:<p>Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against</p>Fórmula:C24H26N4O4Forma y color:SolidPeso molecular:434.49DMPQ dihydrochloride
CAS:<p>PDGFRβ inhibitor</p>Fórmula:C16H16Cl2N2O2Pureza:99.51%Forma y color:SolidPeso molecular:339.22AhR modulator-1
CAS:<p>AhR modulator-1: orally active, selective, inhibits metastasis and prostatic VEGF, anti-estrogenic in rat uterus.</p>Fórmula:C13H7Cl3OPureza:98%Forma y color:SolidPeso molecular:285.55PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Forma y color:SolidPeso molecular:441.27FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Fórmula:C25H28F2N8Forma y color:SolidPeso molecular:478.54Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Fórmula:C23H22F5N7OForma y color:SolidPeso molecular:507.469FAK-IN-5
CAS:<p>FAK-IN-5 is a FAK signaling inhibitor that induces apoptosis and autophagy.</p>Fórmula:C29H29ClF3N3O4Forma y color:SolidPeso molecular:576.01JS25
CAS:<p>JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.</p>Fórmula:C29H24N4O4SForma y color:SolidPeso molecular:524.59FLT3-IN-11
CAS:<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Fórmula:C20H25F3N6OForma y color:SolidPeso molecular:422.45(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OForma y color:SolidPeso molecular:285.34(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.34-DAMP
CAS:<p>4-DAMP (4-DAMP methiodide) is a selective muscarinic M1 and M3 subtype receptor antagonist used in the study of allergic rhinitis and cardiovascular disease.</p>Fórmula:C21H26INO2Pureza:98%Forma y color:SolidPeso molecular:451.34EGFR-IN-40
CAS:<p>EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).</p>Fórmula:C23H20N6O3Forma y color:SolidPeso molecular:428.44QL-X-138
CAS:<p>QL-X-138: Dual BTK/MNK inhibitor; covalent to BTK, IC50=9.4 nM; non-covalent to MNK1/2, IC50=107.4/26 nM; dengue virus 2 IC50=3.5 μM; for B-cell malignancies.</p>Fórmula:C25H19N5O2Pureza:98.82% - 99.50%Forma y color:SolidPeso molecular:421.45EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32Derazantinib Racemate
CAS:<p>Derazantinib Racemate is an oral ATP competitive kinase inhibitor targeting FGFR1/2/3 (IC50s: 4.5/1.8/4.5 nM).</p>Fórmula:C29H29FN4OPureza:98%Forma y color:SolidPeso molecular:468.57FGFR-IN-3
CAS:<p>FGFR-IN-3: potent, oral FGFR modulator, BBB-penetrating, neuroprotective, potential in neurodegeneration study.</p>Fórmula:C18H27F2N5O2Forma y color:SolidPeso molecular:383.44PF-06465469
CAS:<p>PF-06465469 is a covalent ITK inhibitor(IC50: 2 nM).</p>Fórmula:C30H33N7O2Pureza:98%Forma y color:SolidPeso molecular:523.63EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Fórmula:C16H16BrN3OPureza:98% - 99.6%Forma y color:SolidPeso molecular:346.22TC-S 7009
CAS:<p>TC-S 7009: Strong HIF-2α inhibitor (Kd 81 nM), weak for HIF-1α; disrupts dimerization & gene expression.</p>Fórmula:C12H6ClFN4O3Pureza:99.46% - 99.71%Forma y color:SolidPeso molecular:308.65Dasatinib hydrochloride
CAS:<p>Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).</p>Fórmula:C22H27Cl2N7O2SPureza:99.88% - 99.98%Forma y color:SolidPeso molecular:524.47MBM-55
CAS:<p>MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM.</p>Fórmula:C28H27FN6O2Pureza:99.83%Forma y color:SolidPeso molecular:498.55NX-2127
CAS:<p>NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative</p>Fórmula:C39H45N9O5Pureza:99.07%Forma y color:SolidPeso molecular:719.83PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Forma y color:SolidPeso molecular:330.38A 419259 trihydrochloride
CAS:A 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).Fórmula:C29H37Cl3N6OPureza:99.75% - 99.96%Forma y color:SolidPeso molecular:592A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Forma y color:SolidPeso molecular:352.35Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Fórmula:C40H38ClNO5Pureza:99.97%Forma y color:SolidPeso molecular:648.19SI-2 hydrochloride
CAS:<p>SI-2 hydrochloride, an SRC-3 inhibitor, induces breast cancer cell death (IC50: 3-20 nM) with good oral bioavailability.</p>Fórmula:C15H16ClN5Pureza:98.6%Forma y color:SolidPeso molecular:301.77WDR5-0102
CAS:<p>WDR5-0102 inhibits WDR5-MLL1 (Kd=4 μM), blocks MLL1 HMT activity, but doesn't affect SETD7 and 6 other HMTs.</p>Fórmula:C18H19ClN4O3Pureza:98.03%Forma y color:SolidPeso molecular:374.82P505-15 Acetate
CAS:<p>P505-15 Acetate inhibits spleen tyrosine kinase, reduces immune response and inflammation, and lowers arthritis severity.</p>Fórmula:C21H27N9O3Pureza:99.99%Forma y color:SolidPeso molecular:453.5BMS-605541
CAS:<p>BMS-605541 is a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity(Ki=49 nM).</p>Fórmula:C19H17F2N5OSPureza:98.07%Forma y color:SolidPeso molecular:401.43Tafetinib
CAS:<p>Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.</p>Fórmula:C24H29FN4O2Pureza:96.23%Forma y color:SolidPeso molecular:424.51CTA 056
CAS:<p>CTA 056 is an ITK inhibitor that inhibits the growth of MOLT-4 xenograft tumors in mice and can be used to study autoimmune disorders.</p>Fórmula:C35H34N6OPureza:97.22% - 97.76%Forma y color:SolidPeso molecular:554.68CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Fórmula:C25H24ClN7O2Pureza:99.66%Forma y color:SolidPeso molecular:489.96EGFR-IN-11
CAS:<p>EGFR-IN-11 selectively blocks EGFR-tyrosine kinase and promotes apoptosis; targets EGFRL858R/T790M/C797S, IC50=18 nM; halts cell cycle at G0/G1.</p>Fórmula:C29H35N9O2SPureza:99.93%Forma y color:SolidPeso molecular:573.71Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Forma y color:SoildPeso molecular:591.55JNJ-49095397
CAS:<p>JNJ-49095397 (RV568) is a p38 MAPK-α and p38 MAPK-γ kinase inhibitor for the study of respiratory syncytial virus infection.</p>Fórmula:C34H36N6O4Pureza:98.33% - 99.04%Forma y color:SolidPeso molecular:592.69STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Forma y color:SolidPeso molecular:318.76c-Fms-IN-3
CAS:c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.Fórmula:C23H30N6OPureza:99.87%Forma y color:SolidPeso molecular:406.52TP0427736 hydrochloride
CAS:<p>TP0427736 hydrochloride is a novel and selective ALK5 inhibitor, capable of inhibiting Smad2/3 phosphorylation in A549 cells.</p>Fórmula:C14H11ClN4S2Pureza:98.99%Forma y color:SolidPeso molecular:334.85H-9 dihydrochloride
CAS:<p>H-9 dihydrochloride: Strong PKA inhibitor, curbs 5-HT response and EGF signaling, affects pharyngeal function.</p>Fórmula:C11H15Cl2N3O2SPureza:97.3%Forma y color:SolidPeso molecular:324.23Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Forma y color:Yellow Green Powder /Off-White SolidPeso molecular:202.17HIF-2α-IN-3
CAS:<p>HIF-2α-IN-3 is an allosteric inhibitor of HIF-2α (IC50: 0.4 μM; KD: 1.1 μM) with anticancer activity.</p>Fórmula:C12H6ClN5O5Pureza:98.11%Forma y color:SolidPeso molecular:335.66JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Forma y color:SolidPeso molecular:684.69JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Forma y color:SolidPeso molecular:466.341ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Fórmula:C30H35F3N6O3Pureza:98%Forma y color:SolidPeso molecular:584.63EGFR kinase inhibitor 1
CAS:<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Fórmula:C30H31N7O2Forma y color:SolidPeso molecular:521.61Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Pureza:95%Forma y color:LiquidBTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Forma y color:SolidPeso molecular:662.78FGFR-IN-2
CAS:<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Fórmula:C25H30N6O2Forma y color:SolidPeso molecular:446.54T338C Src-IN-1
CAS:<p>T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).</p>Fórmula:C17H20N6O2SPureza:98%Forma y color:SolidPeso molecular:372.44UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Fórmula:C30H42N6O2Forma y color:SolidPeso molecular:518.69Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Forma y color:SolidPeso molecular:416.43ALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Fórmula:C26H29ClD3N5O3SPureza:98%Forma y color:SolidPeso molecular:533.1DW10075
CAS:<p>DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.</p>Fórmula:C29H23N5O3Forma y color:SolidPeso molecular:489.52Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Fórmula:C17H20N6O4SForma y color:SolidPeso molecular:404.45TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Fórmula:C26H27Cl2N5O2Pureza:98%Forma y color:SolidPeso molecular:512.43JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Fórmula:C33H34N8O2Forma y color:SolidPeso molecular:574.68TIE-2/VEGFR-2 kinase-IN-3
CAS:<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Fórmula:C23H17F4N5O3SForma y color:SolidPeso molecular:519.47JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Forma y color:SolidPeso molecular:379.37EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PForma y color:SolidPeso molecular:610.49FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Fórmula:C25H22N4O5Forma y color:SolidPeso molecular:458.47JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Forma y color:SolidPeso molecular:354.2FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Forma y color:SolidPeso molecular:442.523BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OForma y color:SolidPeso molecular:445.35Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Fórmula:C27H33FN4O7Forma y color:SolidPeso molecular:544.57KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Forma y color:SolidPeso molecular:555.03Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Fórmula:C13H19BrN4Pureza:99.34%Forma y color:SolidPeso molecular:311.22PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Fórmula:C26H30N6OPureza:98%Forma y color:SolidPeso molecular:442.56SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Fórmula:C51H66N10O7S2Forma y color:SolidPeso molecular:995.26SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Fórmula:C18H19NO5Pureza:98%Forma y color:SolidPeso molecular:329.35MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Fórmula:C25H16ClF2N5O2Forma y color:SolidPeso molecular:491.88BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Forma y color:SolidPeso molecular:487.94BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Fórmula:C22H15BCl2N2O2Pureza:98%Forma y color:SolidPeso molecular:421.08HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Fórmula:C16H8F5NO4SPureza:97.99%Forma y color:SolidPeso molecular:405.3EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SForma y color:SolidPeso molecular:729.57Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Fórmula:C26H29ClN8OForma y color:SolidPeso molecular:505.01HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Fórmula:C31H41N7O4Forma y color:SolidPeso molecular:575.7UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Fórmula:C30H44N6OForma y color:SolidPeso molecular:504.71EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Fórmula:C19H21N5O3Pureza:97.4%Forma y color:SolidPeso molecular:367.4Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Forma y color:SolidPeso molecular:602.521BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Fórmula:C29H26FN5O3Pureza:98%Forma y color:SolidPeso molecular:511.55FGFR-IN-4
CAS:<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Fórmula:C24H21N7O2Forma y color:SolidPeso molecular:439.47HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Fórmula:C19H22Cl2N6OSForma y color:SolidPeso molecular:453.39FC 11
CAS:<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Fórmula:C41H42F3N13O9SForma y color:SolidPeso molecular:949.91HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Forma y color:SolidPeso molecular:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Forma y color:SolidPeso molecular:495.02ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Fórmula:C27H34ClN7O3SForma y color:SolidPeso molecular:572.12HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Fórmula:C25H26Cl2N6O3Forma y color:SolidPeso molecular:529.42(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Forma y color:SolidPeso molecular:457.36MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Fórmula:C29H23F3N4O2Pureza:98%Forma y color:SolidPeso molecular:516.51TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Forma y color:SolidPeso molecular:344.39EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PForma y color:SolidPeso molecular:733.68JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Fórmula:C23H25N7O2Forma y color:SolidPeso molecular:431.49BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OForma y color:SolidPeso molecular:433.33Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Fórmula:C27H24ClF2N5O4Forma y color:SolidPeso molecular:555.96DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Forma y color:SolidPeso molecular:547.56Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Forma y color:SolidPeso molecular:383.41PI3K/VEGFR2-IN-1
CAS:<p>PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.</p>Fórmula:C17H14ClN3OSPureza:98%Forma y color:SolidPeso molecular:343.83TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Fórmula:C30H30N4O3Pureza:98%Forma y color:SolidPeso molecular:494.58Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Fórmula:C29H35Cl2N7O5Forma y color:SolidPeso molecular:632.54ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Fórmula:C27H34ClN7O3SPureza:98%Forma y color:SolidPeso molecular:572.12EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Forma y color:SolidPeso molecular:538.64Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Fórmula:C28H32F2N6O5Pureza:99.08% - 99.38%Forma y color:SolidPeso molecular:570.59HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Fórmula:C24H28N6O3Pureza:98%Forma y color:SolidPeso molecular:448.52SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Fórmula:C28H35ClFN7O3SForma y color:SolidPeso molecular:604.14CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Fórmula:C22H25BrF5N5O5SPureza:98%Forma y color:SolidPeso molecular:646.43ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Fórmula:C27H34ClN7O3SForma y color:SolidPeso molecular:572.12AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Fórmula:C22H29N7O5Pureza:98%Forma y color:SolidPeso molecular:471.52BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Fórmula:C29H34N8O3Forma y color:SolidPeso molecular:542.63FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Fórmula:C25H24N6O2SForma y color:SolidPeso molecular:472.56BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Forma y color:SolidPeso molecular:567.01JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Forma y color:SolidPeso molecular:527.66BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Forma y color:SolidPeso molecular:465.51PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Forma y color:SolidPeso molecular:473.92Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Fórmula:C30H52N2O8Forma y color:SolidPeso molecular:568.74Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Fórmula:C25H26ClFN4O4Pureza:99.7%Forma y color:SolidPeso molecular:500.95TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Fórmula:C26H17F4N5O4Forma y color:SolidPeso molecular:539.44Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Fórmula:C24H28N6O3SPureza:99.21% - >99.99%Forma y color:SolidPeso molecular:480.58CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Fórmula:C18H18ClNO4S3Pureza:98%Forma y color:SolidPeso molecular:443.99EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Fórmula:C30H29ClN6OPureza:98%Forma y color:SolidPeso molecular:525.04Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Fórmula:C10H18O4Pureza:≥98%Forma y color:SolidPeso molecular:202.25(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Forma y color:SolidPeso molecular:266.29
